Crystalvue Medical Corporation (TPEX:6527)
Taiwan · Delayed Price · Currency is TWD 76.80
+0.50 (0.66%)
Jan 22, 2026, 1:18 PM CST
Crystalvue Medical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 905.73 | 868.03 | 823.96 | 795.46 | 721.61 | 504.37 | Upgrade | |
Revenue Growth (YoY) | 8.65% | 5.35% | 3.58% | 10.23% | 43.07% | -23.71% | Upgrade |
Cost of Revenue | 588.29 | 568.89 | 557.22 | 533.71 | 510.22 | 338.98 | Upgrade |
Gross Profit | 317.45 | 299.14 | 266.75 | 261.74 | 211.39 | 165.39 | Upgrade |
Selling, General & Admin | 106.36 | 108.48 | 104.4 | 89.97 | 73.73 | 66.45 | Upgrade |
Research & Development | 41.39 | 45.66 | 44.67 | 46.97 | 49.2 | 41.28 | Upgrade |
Operating Expenses | 147.75 | 154.14 | 149.07 | 136.94 | 122.93 | 107.73 | Upgrade |
Operating Income | 169.7 | 145.01 | 117.68 | 124.8 | 88.47 | 57.66 | Upgrade |
Interest Expense | -0.5 | -0.63 | -0.82 | -1 | -1.17 | -1.34 | Upgrade |
Interest & Investment Income | 2.48 | 2.14 | 1.47 | 0.47 | 1.06 | 1.89 | Upgrade |
Earnings From Equity Investments | - | - | - | - | - | -0.02 | Upgrade |
Currency Exchange Gain (Loss) | -4.09 | 6.33 | 1.19 | 10.68 | -2.11 | -4.55 | Upgrade |
Other Non Operating Income (Expenses) | 0.62 | 6.53 | 0.22 | 7.48 | 8.97 | 9.33 | Upgrade |
EBT Excluding Unusual Items | 168.2 | 159.38 | 119.74 | 142.44 | 95.22 | 62.97 | Upgrade |
Gain (Loss) on Sale of Assets | 0.28 | - | - | - | 13.95 | - | Upgrade |
Pretax Income | 168.48 | 159.38 | 119.74 | 142.44 | 109.17 | 62.97 | Upgrade |
Income Tax Expense | 29.21 | 32.23 | 16.34 | 27.41 | 31.93 | 6.35 | Upgrade |
Net Income | 139.27 | 127.15 | 103.4 | 115.03 | 77.24 | 56.62 | Upgrade |
Net Income to Common | 139.27 | 127.15 | 103.4 | 115.03 | 77.24 | 56.62 | Upgrade |
Net Income Growth | 20.30% | 22.98% | -10.11% | 48.93% | 36.42% | -37.84% | Upgrade |
Shares Outstanding (Basic) | 25 | 25 | 25 | 25 | 25 | 25 | Upgrade |
Shares Outstanding (Diluted) | 26 | 26 | 25 | 26 | 25 | 26 | Upgrade |
Shares Change (YoY) | 0.84% | 1.64% | -0.91% | 0.53% | -0.99% | 13.00% | Upgrade |
EPS (Basic) | 5.50 | 5.02 | 4.13 | 4.59 | 3.08 | 2.23 | Upgrade |
EPS (Diluted) | 5.41 | 4.95 | 4.09 | 4.51 | 3.05 | 2.21 | Upgrade |
EPS Growth | 19.54% | 21.03% | -9.31% | 47.98% | 37.93% | -45.02% | Upgrade |
Free Cash Flow | -101.53 | 22.62 | 149.64 | 44.24 | -287.91 | 53.77 | Upgrade |
Free Cash Flow Per Share | -3.94 | 0.88 | 5.92 | 1.73 | -11.35 | 2.10 | Upgrade |
Dividend Per Share | 2.250 | 2.250 | 2.070 | 2.286 | 1.848 | 1.333 | Upgrade |
Dividend Growth | 8.70% | 8.70% | -9.44% | 23.71% | 38.57% | -45.10% | Upgrade |
Gross Margin | 35.05% | 34.46% | 32.37% | 32.91% | 29.29% | 32.79% | Upgrade |
Operating Margin | 18.74% | 16.71% | 14.28% | 15.69% | 12.26% | 11.43% | Upgrade |
Profit Margin | 15.38% | 14.65% | 12.55% | 14.46% | 10.70% | 11.22% | Upgrade |
Free Cash Flow Margin | -11.21% | 2.61% | 18.16% | 5.56% | -39.90% | 10.66% | Upgrade |
EBITDA | 181.3 | 165.75 | 139.51 | 143.92 | 122.55 | 76.31 | Upgrade |
EBITDA Margin | 20.02% | 19.10% | 16.93% | 18.09% | 16.98% | 15.13% | Upgrade |
D&A For EBITDA | 11.6 | 20.75 | 21.83 | 19.11 | 34.09 | 18.66 | Upgrade |
EBIT | 169.7 | 145.01 | 117.68 | 124.8 | 88.47 | 57.66 | Upgrade |
EBIT Margin | 18.74% | 16.71% | 14.28% | 15.69% | 12.26% | 11.43% | Upgrade |
Effective Tax Rate | 17.34% | 20.22% | 13.65% | 19.25% | 29.25% | 10.08% | Upgrade |
Advertising Expenses | - | - | - | - | 26.55 | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.